197 related articles for article (PubMed ID: 8261678)
1. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism.
Fischer ER; Harris DC
Clin Nephrol; 1993 Oct; 40(4):216-20. PubMed ID: 8261678
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
4. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
[TBL] [Abstract][Full Text] [Related]
7. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
Malberti F; Surian M; Cosci P
Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
[TBL] [Abstract][Full Text] [Related]
8. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
9. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
[TBL] [Abstract][Full Text] [Related]
10. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
Dressler R; Laut J; Lynn RI; Ginsberg N
Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
[TBL] [Abstract][Full Text] [Related]
11. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
12. [Intravenous calcitriol in the treatment of the refractory secondary hyperparathyroidism of terminal chronic kidney failure].
Almirall J; Torregrosa V; Arrizabalaga P; Cases A; Oliva J
Med Clin (Barc); 1994 Mar; 102(9):325-8. PubMed ID: 8164458
[TBL] [Abstract][Full Text] [Related]
13. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
14. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study.
Tsuruoka S; Sugimoto K; Ohmori M; Kawaguchi A; Saito T; Fujimura A
Clin Pharmacol Ther; 1999 Dec; 66(6):609-16. PubMed ID: 10613617
[TBL] [Abstract][Full Text] [Related]
15. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
Neyer U; Wöss E; Drexel H
Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
[TBL] [Abstract][Full Text] [Related]
16. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
[TBL] [Abstract][Full Text] [Related]
18. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
Indridason OS; Quarles LD
Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
[TBL] [Abstract][Full Text] [Related]
19. [Oral calcitriol pulse therapy in treatment of secondary hyperparathyroidism in patients with long term hemodialysis].
Szołkiewicz M; Zdrojewski Z; Sulima-Gillow A; Rutkowski B
Przegl Lek; 1996; 53(5):427-30. PubMed ID: 8754407
[TBL] [Abstract][Full Text] [Related]
20. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
Daisley-Kydd RE; Mason NA
Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
